
    
      A randomized, double-blind two-way crossover study of three cumulative doses of arformoterol
      (7.5 ug per nebulization) and levalbuterol (0.63 mg per nebulization) given over a one hour
      period, followed by a single open-label treatment day with three cumulative doses of
      arformoterol 15 ug in subjects 2-11 years of age with asthma. This study was previously
      posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo
      Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals
      Inc.
    
  